Shionogi & Co Ltd Executive and Leadership Team

Takeshi Kasuya, the Chief Executive Officer at Shionogi & Co Ltd, directs the overarching corporate strategy to ensure long-term growth within the competitive pharmaceutical landscape. By prioritizing the development of novel therapies for infectious diseases, the Chief Executive Officer aligns internal research capabilities with global market demands. Kasuya oversees the integration of biotech collaborations to accelerate the delivery of life-saving treatments to patients across international markets. This leadership role involves constant engagement with the Board to refine operational efficiency and maintain high standards of scientific excellence. Through rigorous oversight of the company's R&D pipeline, Takeshi Kasuya drives the advancement of antibiotic and antiviral programs. The Chief Executive Officer maintains a focus on sustainable innovation, ensuring that the organization remains at the forefront of medical breakthroughs while navigating complex regulatory environments to secure the future of the enterprise.

Isao Teshirogi, the Representative Director, President & Chief Executive Officer at Shionogi & Co Ltd, manages the executive vision and organizational culture to foster scientific progress. As the primary leader, the Representative Director, President & Chief Executive Officer coordinates cross-functional teams to address urgent global health challenges, including influenza and COVID-19. Teshirogi architects strategic partnerships with government agencies and academic institutions to expand the reach of the company's therapeutic portfolio. This role requires balancing immediate operational needs with long-term scientific goals to improve patient outcomes worldwide. By championing a culture of precision and urgency, Isao Teshirogi ensures that the organization effectively translates complex research into tangible medical solutions. The Representative Director, President & Chief Executive Officer maintains a strong focus on market expansion, guiding the company through diverse geographic landscapes to solidify the firm's position as a leader in the pharmaceutical industry.

Masahiro Fujita, the Senior Vice President & Chief Financial Officer at Shionogi & Co Ltd, manages the financial health and capital allocation strategies necessary to support large-scale pharmaceutical development. The Senior Vice President & Chief Financial Officer oversees fiscal planning, risk management, and investor relations to ensure the company maintains the resources required for high-stakes research programs. Fujita directs the financial analysis of global operations, providing the data-driven insights needed for the Board to make informed decisions regarding R&D investments. By optimizing the capital structure, the Senior Vice President & Chief Financial Officer supports the company's mission to deliver novel therapies for infectious diseases. Masahiro Fujita ensures that financial performance aligns with the strategic objectives of the firm, maintaining transparency and accountability across all departments. This leadership role involves rigorous monitoring of market trends to safeguard the company's economic stability while funding the next generation of medical breakthroughs.

Tsutae (Den) Nagata, the Chief Medical Officer at Shionogi & Co Ltd, directs the clinical development and medical affairs strategy to ensure the safety and efficacy of all pharmaceutical products. The Chief Medical Officer oversees the transition of novel therapies from laboratory research to clinical trials, ensuring compliance with international health standards. Nagata manages the medical team's interactions with regulatory bodies to expedite the approval of treatments for HIV and other viral threats. By providing clinical expertise, the Chief Medical Officer guides the company's research programs toward successful patient outcomes. Tsutae (Den) Nagata collaborates with global health organizations to address unmet medical needs, ensuring that the company's scientific advancements meet the highest quality benchmarks. This leadership role involves constant evaluation of clinical data to refine therapeutic approaches, ultimately driving the success of the company's mission to improve patient lives through innovative and precise medical interventions.